HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Nobuyo Maeda Selected Research

lipoic acid synthase

10/2020New insights into immunomodulation via overexpressing lipoic acid synthase as a therapeutic potential to reduce atherosclerosis.
1/2016Influence of Different Levels of Lipoic Acid Synthase Gene Expression on Diabetic Nephropathy.
7/2012Reduced alpha-lipoic acid synthase gene expression exacerbates atherosclerosis in diabetic apolipoprotein E-deficient mice.
1/2012Reduced expression of lipoic acid synthase accelerates diabetic nephropathy.
8/2010Genetic reduction of lipoic acid synthase expression modestly increases atherosclerosis in male, but not in female, apolipoprotein E-deficient mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Nobuyo Maeda Research Topics

Disease

41Atherosclerosis
10/2020 - 02/2002
10Atherosclerotic Plaque (Atheroma)
01/2017 - 03/2002
10Inflammation (Inflammations)
01/2016 - 04/2006
9Hypertension (High Blood Pressure)
07/2015 - 02/2002
8Insulin Resistance
02/2015 - 07/2004
7Cardiomegaly (Heart Hypertrophy)
02/2014 - 03/2002
7Fibrosis (Cirrhosis)
01/2013 - 02/2006
6Alzheimer Disease (Alzheimer's Disease)
01/2022 - 12/2004
6Hypertrophy
02/2014 - 06/2003
5Cardiovascular Diseases (Cardiovascular Disease)
01/2019 - 05/2005
5Body Weight (Weight, Body)
10/2010 - 06/2003
4Coronary Disease (Coronary Heart Disease)
09/2008 - 12/2002
3Glomerulonephritis
01/2016 - 10/2002
3Diabetic Nephropathies (Diabetic Nephropathy)
01/2016 - 01/2012
3Metabolic Syndrome (Dysmetabolic Syndrome X)
08/2014 - 04/2009
3Lipodystrophy
06/2012 - 11/2009
3Ascorbic Acid Deficiency (Vitamin C Deficiency)
05/2011 - 03/2002
3Hypertriglyceridemia
11/2010 - 05/2008
3Infarction (Infarctions)
10/2010 - 01/2002
3Hyperlipidemias (Hyperlipidemia)
10/2008 - 08/2004
3Hypoalphalipoproteinemias (Hypoalphalipoproteinemia)
08/2007 - 05/2005
3Homocystinuria
08/2007 - 08/2002
3Hyperhomocysteinemia
08/2007 - 08/2003
3Infections
10/2006 - 04/2002
2Pre-Eclampsia (Preeclampsia)
11/2016 - 04/2012
2Glucose Intolerance
08/2014 - 10/2010
2Thrombosis (Thrombus)
11/2011 - 08/2003
2Dyslipidemias (Dyslipidemia)
09/2011 - 11/2009
2Hyperglycemia
05/2011 - 11/2010
2Hepatomegaly
11/2010 - 01/2005
2Rupture
10/2010 - 03/2002
2Tangier Disease
04/2010 - 05/2005
2Ureteral Obstruction
04/2009 - 04/2006
2Vascular Remodeling
04/2009 - 06/2007
2Hyperlipoproteinemia Type II (Familial Hypercholesterolemia)
10/2008 - 01/2007
2Hypercholesterolemia
01/2007 - 09/2005
2Hyperlipoproteinemia Type III (Broad Beta Disease)
01/2007 - 09/2002
2Neurodegenerative Diseases (Neurodegenerative Disease)
08/2006 - 04/2006
2Heart Failure
02/2006 - 04/2005
2Chronic Granulomatous Disease
10/2004 - 06/2002

Drug/Important Bio-Agent (IBA)

29ApolipoproteinsIBA
10/2020 - 03/2002
29Apolipoproteins E (ApoE)IBA
10/2020 - 02/2002
15CholesterolIBA
01/2014 - 09/2002
11LipidsIBA
02/2015 - 03/2003
9Apolipoprotein E4IBA
01/2022 - 01/2004
9LDL Receptors (LDL Receptor)IBA
09/2011 - 01/2004
9PPAR gammaIBA
03/2010 - 07/2004
7AntioxidantsIBA
10/2020 - 03/2002
6Apolipoprotein E2IBA
01/2022 - 04/2006
6Proteins (Proteins, Gene)FDA Link
01/2017 - 03/2004
6CollagenIBA
01/2016 - 03/2002
6Insulin (Novolin)FDA Link
02/2015 - 11/2009
6Lipoproteins (Lipoprotein)IBA
02/2013 - 01/2005
5Apolipoprotein E3IBA
01/2022 - 01/2004
5lipoic acid synthaseIBA
10/2020 - 08/2010
5Glucose (Dextrose)FDA LinkGeneric
02/2015 - 07/2004
5EnzymesIBA
06/2014 - 06/2002
5Protein Isoforms (Isoforms)IBA
09/2011 - 08/2004
5Atrial Natriuretic Factor (ANF)IBA
12/2009 - 04/2005
4LDL Lipoproteins (beta Lipoproteins)IBA
01/2019 - 01/2005
4LDL CholesterolIBA
01/2019 - 05/2007
4Peroxisome Proliferator-Activated Receptors (PPAR)IBA
01/2016 - 03/2010
4Ascorbic Acid (Vitamin C)FDA LinkGeneric
05/2011 - 03/2002
4Natriuretic PeptidesIBA
12/2009 - 06/2003
4NF-kappa B (NF-kB)IBA
04/2009 - 10/2006
4Peroxidase (Myeloperoxidase)IBA
07/2005 - 01/2002
3AutoantibodiesIBA
01/2016 - 10/2002
3Matrix Metalloproteinases (MMPs)IBA
01/2016 - 06/2009
3Rosiglitazone (Avandia)FDA Link
02/2014 - 03/2009
3Triglycerides (Triacylglycerol)IBA
01/2014 - 05/2008
3Thioctic Acid (Lipoic Acid)IBA
07/2012 - 08/2006
3Transcription Factors (Transcription Factor)IBA
05/2011 - 02/2007
3Messenger RNA (mRNA)IBA
09/2010 - 10/2006
3oxidized low density lipoproteinIBA
04/2010 - 01/2007
3atrial natriuretic factor receptor AIBA
04/2009 - 06/2003
3LigandsIBA
03/2009 - 03/2003
3Apolipoprotein A-I (Apolipoprotein A1)IBA
08/2007 - 05/2005
3Cystathionine beta-Synthase (Serine Sulfhydrase)IBA
08/2007 - 08/2003
3ChemokinesIBA
07/2003 - 04/2002
2c-Mer Tyrosine KinaseIBA
01/2017 - 01/2015
2Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
07/2015 - 09/2008
2Adenosine Triphosphate (ATP)IBA
06/2014 - 03/2004
2DiureticsIBA
02/2014 - 02/2006
2Streptozocin (Streptozotocin)FDA Link
07/2012 - 08/2006
2Nitric Oxide (Nitrogen Monoxide)FDA Link
04/2012 - 08/2007
2ThiazolidinedionesIBA
10/2010 - 03/2009
23' Untranslated Regions (3' UTR)IBA
09/2010 - 05/2007
2Apolipoproteins B (ApoB)IBA
04/2010 - 10/2008
2Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
06/2009 - 10/2006
2Tissue Inhibitor of Metalloproteinase-3IBA
06/2007 - 04/2006
2Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA
10/2006 - 03/2003
2AldosteroneIBA
02/2006 - 04/2005
2ReninIBA
02/2006 - 04/2005
2CCR2 ReceptorsIBA
06/2005 - 03/2003
2salicylhydroxamic acid (SHAM)IBA
04/2005 - 03/2002
2NADPH Oxidases (NAD(P)H oxidase)IBA
10/2004 - 06/2002
2HomocysteineIBA
08/2003 - 08/2002
2Oxidoreductases (Dehydrogenase)IBA
06/2002 - 03/2002

Therapy/Procedure

3Therapeutics
06/2014 - 12/2002
3Bone Marrow Transplantation (Transplantation, Bone Marrow)
06/2005 - 03/2003